Motif Bio PLC UPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL (2555J)

TIDMMTFB

RNS Number : 2555J

Motif Bio PLC

08 September 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

This announcement contains inside information.

Motif Bio plc

("Motif Bio" or the "Company")

8 September 2016

UPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces an update to REVIVE-1, one of Motif Bio's two Phase 3 clinical trials currently enrolling patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Patient enrollment for REVIVE-1 has exceeded projections and data readout is now expected in the second quarter of 2017, rather than the second half of 2017, as previously stated. REVIVE-2 remains on track with data readout continuing to be expected in the second half of 2017.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further information please contact:

 
 Motif Bio plc                                               [e-mail] 
  Richard Morgan (Chairman) 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited 
  (NOMAD & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                           [phone] 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/ David 
  Hignell 
  John Howes/ Rob Rees 
  (Broking)                                                [phone] 
 Walbrook PR Ltd. (FINANCIAL    [phone] or [e-mail] 
  PR & IR)                                            Mob: [phone] 
  Paul McManus                                        Mob: [phone] 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                            [phone] 
 

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to be completed in 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLFFLVAVIDIIR

(END) Dow Jones Newswires

September 08, 2016 02:01 ET (06:01 GMT)